What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?
3 equities research analysts have issued 1 year price targets for Retrophin's shares. Their predictions range from $28.00 to $46.00. On average, they expect Retrophin's share price to reach $35.33 in the next year.
When will Retrophin announce their earnings?
Retrophin is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Retrophin stock?
Here are some recent quotes from research analysts about Retrophin stock:
According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (1/11/2017)
Leerink Swann analysts commented, "We believe the quarter signals turnaround on repricing in the core MA book of business." (5/11/2016)
Who owns Retrophin stock?
Retrophin's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.66%), Perceptive Advisors LLC (7.12%), FMR LLC (4.16%), State Street Corp (3.18%), Franklin Resources Inc. (2.86%) and Kingdon Capital Management L.L.C. (1.10%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur and Steve Aselage.
Who sold Retrophin stock? Who is selling Retrophin stock?
Retrophin's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Broadfin Capital LLC, Two Sigma Investments LP, Wall Street Associates, Oxford Asset Management, Franklin Resources Inc., Tudor Investment Corp Et Al and AQR Capital Management LLC. Company insiders that have sold Retrophin stock in the last year include Alvin Shih and Steve Aselage.
Who bought Retrophin stock? Who is buying Retrophin stock?
Retrophin's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Bogle Investment Management L P DE, State Street Corp, Dimensional Fund Advisors LP, Paulson & CO. Inc., Renaissance Technologies LLC, Kingdon Capital Management L.L.C. and Russell Investments Group Ltd..
How do I buy Retrophin stock?
Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Retrophin stock cost?
One share of Retrophin stock can currently be purchased for approximately $20.67.